Madrigal Graham Net Net from 2010 to 2024

MDGL Stock  USD 312.00  1.13  0.36%   
Madrigal Pharmaceuticals Graham Net Net yearly trend continues to be quite stable with very little volatility. The value of Graham Net Net is projected to decrease to 20.28. From the period between 2010 and 2024, Madrigal Pharmaceuticals, Graham Net Net regression line of its data series had sample variance of  4,875 and sample variance of  4,875. View All Fundamentals
 
Graham Net Net  
First Reported
2010-12-31
Previous Quarter
21.34641611
Current Value
20.28
Quarterly Volatility
69.82422807
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 13.3 M, Other Operating Expenses of 399.5 M or Research Development of 286 M, as well as many indicators such as Price To Sales Ratio of 3.4 K, Dividend Yield of 0.0073 or PTB Ratio of 11.2. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Latest Madrigal Pharmaceuticals' Graham Net Net Growth Pattern

Below is the plot of the Graham Net Net of Madrigal Pharmaceuticals over the last few years. It is Madrigal Pharmaceuticals' Graham Net Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Madrigal Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Graham Net Net10 Years Trend
Very volatile
   Graham Net Net   
       Timeline  

Madrigal Graham Net Net Regression Statistics

Arithmetic Mean38.55
Coefficient Of Variation181.12
Mean Deviation36.45
Median20.28
Standard Deviation69.82
Sample Variance4,875
Range286
R-Value(0.11)
Mean Square Error5,190
R-Squared0.01
Significance0.70
Slope(1.68)
Total Sum of Squares68,256

Madrigal Graham Net Net History

2024 20.28
2023 21.35
2022 11.3
2021 11.68
2020 15.35
2019 26.86
2018 60.93

About Madrigal Pharmaceuticals Financial Statements

Madrigal Pharmaceuticals investors utilize fundamental indicators, such as Graham Net Net, to predict how Madrigal Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Graham Net Net 21.35  20.28 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.03)
Revenue Per Share
3.705
Return On Assets
(0.52)
Return On Equity
(1.30)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.